Alsenz, J., K. Bork, and M. Loos. 1987. Autoantibody-mediated acquired deficiency of C1 inhibitor. N Engl J Med 316:1360-1366.
Baker, M. S, P. Bleakley, G. C. Woodrow, and W. F. Doe. 1990. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.Cancer Res 50(15):4676-4684.
Beinrohr, L., V. Harmat, J. Dobo, L. Zsolt, P. Gal, and P. Zavodszky. 2007. C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease. J Biol Chem 282:21100-21209.
Bensa, J. C., A. Reboul, and M. G. Colomb. 1983. Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes. Biochem J 216(2):385-392.
Bergamaschini, L., G. Gobbo, S. Gatti, L. Caccamo, P. Prato, M. Maggioni, P. Braidotti, R. Di Stefano, and L. R. Fassati. 2001. Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin Exp Immunol 126:412-420.
Bock, S. C., K. Skriver, E. Nielsen, H. C. Thøgersen, B. Wiman, V. H. Donaldson, R. L. Eddy, J. Marrinan, E. Radziejewska, and R. Huber. 1986. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25:4292-4301.
Cai, S., and A. E. Davis. 2003. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol 171:4786-4791.
Cai, S., V. Dole, W. Bergmeier, J. Scafidi, H. Feng, D. D. Wagner, and A. E. Davis. 2005. A direct role for C1 inhibitor in leukocyte adhesion. J Immunol 174:6462-6466.
Cajot, J. F., J. Bamat, G. E. Bergonzelli, E. K. Kruithof, R. L. Medcalf, J. Testuz, and B. Sordat. 1990. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci U S A 87(18):6939-6943.
Carter, P. E., C. Duponchel, M. Tosi ,and J. E. Fothergill. 1991. Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. Eur J Biochem 197:301-308.
Castelli, R., D. L. Deliliers, L. C. Zingale, E. M. Pogliani, and M. Cicardi. 2007. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica 92:716-718.
Cicardi, M., G. Bisiani, M. Cungo, P. Spaeth, and A. Agostoni. 1993. Autoimmune C1-inhibitor deficiency. Report of eight patients. Am J Med
95:169-175.
Cohen, S. H., S. M. Koethe, F. Kozin, G. Rodey, J. A. Arkins, and J. N. Fink. 1978. Acquired angioedema associated with retal carcinoma and its response to danazol therapy. J Immunol 62:217-212.
Colten, H. R. 1972. Ontogeny of the Human Complement System: In Vitro Biosynthesis of Individual Complement Components by Fetal Tissues. J Cli Invest 51:725-730.
Coutinho, M., K. S. Aulak, and A. E. Davis 3rd. 1994. Functional analysis of the serpin domain of C1 inhibitor. J Immunol 153:3648-3654.
Donaldson, V. H. 1993. C1-inhibitor and its genetic alterations in hereditary angioneurotic edema. Int Rev Immunol 10:1-16.
Farkas, H., A. Csepregi, and E. Nemesanszky. 1999. Acquired angioedema associated with chronic hepatitis C. J Immunol 103:711-712.
Farkas, H., M. Szongoth, and M. Bely. 2001. Angioedema due to acquired deficiency of C1-esterase inhibitor associated with leucocytoclastic vascilitis. Acta Derm Venereol 81:298-300.
Folkerd, E. J., B. Gardner, and N. C. Hughes-Jones. 1980. The relationsip between the binding ability and the rate of activation of the complement component C1. Immunol 41:179-185.
Gadek, J. E., S. W. Hosea, J. A. Gelfand, M. Santaella. 1980. Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.N Engl J Med 302:542-546.
Gulati, P., C. Lemercier, D. Guc, D. Lappin, and W. Whaley. 1993. Regulation of the synthesis of C1 subcomponents and C1-inhibitor. Behring Inst Mitt 93:196-203.
Harrison, R. A. 1983. Human C1 inhibitor: improved isolation and preliminary structural characterization. Biochemistry 22:5001-5007.
He, S., R. B. Sim, and K. Whaley. 1996. Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency.J Immunol 156(5):2009-2013.
He, S., R. B. Sim, and K. Whaley. 1997a. A secondary C1s interaction site on C1-inhibitor is essential for formation of a stable enzyme-inhibitor complex. FEBS Lett 405:42-46.
He, S., J. C. Yang, S. Tsang, R. B. Sim and K. Whaley. 1997b. Role of the distal hinge region of C1-inhibitor in the regulation of C1s activity. FEBS Lett 412:506-510.
He, S., R. B. Sim, and K. Whaley. 1998. Mechanism of Action of Anti-C1-Inhibitor Autoantibodies: Prevention of the Formation of Stable C1s-C1-inh Complexes. Med 4:119-128.
He, S., and R. A. Stockley. 2002. SDS-stable C1 inhibitor-C1s complex is linked by an oxygen bridge: Implication for the formation of stable serpin- enzyme ccomplexes. Recent Res Devel Immunology 4: 803-809.
Iatridis, S. G., and J. H. Ferguson. 1962. Actie Hageman factor: a plasma lysokinase of the human fibrinolytic system. J Clin Invest 41:1277-1287.
Jiang, H., E. Wagner, and M. M. Frank. 2001. Complement 1 inhibitor is regulator of the alternative complement pathway. J Exp Med 1609-1616.
Kaplan, A. P., and K. F. Austen. 1970. A pre-albumin activator of prekallikrein. J Immunol 105(4):802-811.
Kaplan, A. P., and K. F. Austen. 1971. A prealbumin activator of prekallikrein: II.Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin. J Exp Med 133(4):696-712.
Kaplan, A. P., and K. F. Austen. 1972. The fibrinolytic pathway of human plasma. Isolation and characterization of the plasminogen proactivator. J Exp Med 135(6):1378-1393.
Katz, Y., and R. C. Strunk. 1989. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J Immunol 142(6):2041-2045.
Lappin, D. F., G. D. Birnie, and K. Whaley. 1990. Modulation by interferons of the expression of monocyte complement genes. Biochem J 268:387-392
Leibovitz, A. 1963. The growth and maintainance of tissue/cell cultures in free gas exchange with the atmosphere. Amer J Hyg 78:173-180
Levy, N. J., N. Ramesh, M. Cicardi, R. A. Harrison, and A. E. Davis III. 1990. Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine436 in the C1 inhibitor gene. Proc Natl Acad Sci U S A 87:265-268.
Liang, C., A. Y. Park, and J. Guan. 2007. In vitro scratch assay: a conventient and inexpensive method for analysis of cell migration in vitro. Nature Protocols 2:329-333.
Liang, X., J. Huuskonen, M. Hajivandi, and R. Manzanedo. 2009. Identification and quantification of proteins differentially secreated by a pair of normal and malignant breast-cancer cell lines. Proteomics 182-193.
Lin,Y. L.,and S. He. 2006. Sm22.6 antigen is an inhibitor to human thrombin. Molecular&Biochemical Parasitology 147:95-100.
Liu, D., S. cai, Gu. X, J. Scafidi, Wu. X, and A. E. Davis III. 2003. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 171:2594-2601.
Liu, D., C. C. Cramer, J. Scafidi, and A. E. Davis III. 2005. N-linked glycosylation at Asn3 and the positively charged residue within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A. Infect Immun 73:4478-4487.
Lonn, A., M. Garfonyi, W. Van Zyl, B. Hahn-Hägerdal, and R. C. Otero.
2002. Cold adaptation of xylose isomerase from Thermus thermophilus
through random PCR mutagenesis. Gene cloning and protein
characterization. Eur J Biochem 269(1):157-163.
Margolis, J. 1958. Activation of a permeability factor in plasma by contact with glass. Nature 181:635-636.
Miao, R. Q, J. Agata, L. Chao, and J. Chao. 2002. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 100(9):3245-3252.
Mogens. H. N., B. Soren, A. N. Jens, and H. C. Mogens. 1998. C1-esterase inhibitor blocks T lymphocyte proliferation and cytotoxic T lymphocyte generation in vitro. I Immunology 10(2):167-173.
Ogston, D., C. M. Ogston, O. D. Ratnoff, and C. D. Forbes. 1969. Studies
on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. J Clin Invest 48(10):1786-801.
Oltvai, Z. N., E. C. C. Wong, J. P. Atkinson, and K. S. K. Tung. 1991. C1-inhibitor deficiency:molecular and immunological basis of hereditary and acquired angioedema. Lab Invest 65:381-388.
Perkins, S. J., K. F. Smith, S. Amatayakul, D. Ashford, T. W. Rademacher, R. A. Dwek, P.J. Lachmann, and R. A. Harrison. 1990. Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering. J Mol Biol 214: 751-763.
Ratnoff, O. D., and I. Lepow. 1957. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med 106:327-343.
Ratnoff, O. D., E. W. Davie, and D. L. Mallett. 1961. Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. J Clin Inves 40:803-819.
Robles, J. and M. Doers. (1994) pGEM®-T Vector Systems troubleshooting guide. Promega Notes 45:19-20.
Salvesen, G. S., J. J. Catanese, L. F. Kress, and J. Travis. 1985. Primary structure of the reactive site of human C1-inhibitor. J Biol Chem 260: 2432-2436.
Schapira, M., C. F. Scott, and R. W. Colman. 1982. Contribution of plasma protease inhibitots to the inactivation of kallikrein in plasma. J Clin Invest 462-468.
Sim, R. B., A. Reboul, G. J. Arlaud, C. L. Villiers, and M. G. Colomb. 1979. Interation of 125I-labelled complement subcomponents C1r and C1s with protease inhibitors in plasma. FEBS Lett 97:111-115.
Skriver, K., W. R. Wikoff, P. A. Patston, F. Tausk, M. Schapira, A. P. Kaplan, and S. C.Bock . 1991. Substrate properties of C1 inhibitor Ma (alanine 434-glutamic acid). Genetic and structural evidence suggesting that the P12-region contains critical determinants of serine protease inhibitor/substrate status. J Biol Chem 266(14):9216-9221.
Smith, D. B., K. S. Johnson. 1988. Single-step purification of
polypeptides expressed in Escherichia coli as fusions with glutathione
S-transferase. Gene 67 (1):31-40.
Stoppa-Lyonnet, D., C. Duponchel, T. Meo, J. Laurent, P. E. Carter, M. Arala-Chaves, J. H. Cohen, G. Dewald, J. Goetz, G. Hauptmann. 1991. Recombinational biases in the rearranged C1-inhibitor genes of hereditary
angioedema patients. Am J Hum Genet 49:1055-1062.
Webster, M. E, and O. D. Atnoff. 1961. Role of Hageman factor in the activation of vasodilator activity in human plasma. Nature 192:180-181.
Vapnek, D., N. K. Alton, C. L. Bassett, and S. R. Kushner. 1976. Amplification in Escherichia coli of enzymes involved in genetic recombination: construction of hybrid ColE1 plasmids carrying the structural gene for exonuclease I. Proc Natl Acad Sci U S A 73(10):3492-3496.
Xiao, G., Y. E. Liu, R. Gentz, and Y. E. Shi. 1999. Suppression of breast cancer growth and metastasis by a serpin myoepithelium-derived serine proteinase inhibitor expressed in the mammary myoepithelial cells.
Ziccardi, R. J. 1981. Activation of the early components of the classical complement pathway under physiological condictions. J Immunol 1768-1773.
Zingale, L. C., R. Castelli, A. Zanichelli, M. Cicardi. 2006. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. Immunol Allergy Clin North Am 26:669-690.
何世屏,林雅玲,凱斯٠威利(1995年)第一補體抑制蛋白的醣基化多肽的穩定和功能是必需的。中國科學技術(生物部份),347-354
廖彩岑(2008年) SjGST蛋白對人類乳癌細胞的生長及遷移之影響。國立中山大學生物科學系碩士論文